Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis-Reference-Cited by-同舟云学术

Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis

Published:2019-08-28 Issue:1 Volume:21 Page:
ISSN:1478-6362
Container-title:Arthritis Research & Therapy
language:en
Short-container-title:Arthritis Res Ther

Author:

Gu Ki-Nam,Bang So-Young,Lee Hye-Soon,Park Youngho,Kang Ju-Yeon,Kim Ji-Soong,Nam Bora,Yoo Hyun-Seung,Shin Jung-Min,Lee Yeon-Kyung,Lee Tae-Han,Chun Sehwan,Cho Soo-Kyung,Choi Chan-Bum,Sung Yoon-Kyoung,Kim Tae-Hwan,Jun Jae-Bum,Yoo Dae Hyun,Kim Kwangwoo^ORCID,Bae Sang-Cheol

Funder

Kyung Hee University

Ministry of Education

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13075-019-1983-y.pdf

Reference30 articles.

1. Lipsky PE, der Heijde DMFM v, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594–602.

2. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–9.

3. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis. 2009;68:789–96.

4. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35–45.

5. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DPM, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2008;68:69–74.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized medicine in rheumatic diseases: how close are we to being able to use genetic biomarkers to predict response to TNF inhibitors?;Expert Review of Clinical Immunology;2020-03-16